Alexion Pharmaceuticals (ALXN) Receiving Somewhat Positive News Coverage, Analysis Finds
News stories about Alexion Pharmaceuticals (NASDAQ:ALXN) have been trending somewhat positive this week, according to Accern. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alexion Pharmaceuticals earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.8073130030394 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- Alexion loses two executives amid Boston relocation (finance.yahoo.com)
- SunTrust Banks Reiterates “$172.00” Price Target for Alexion Pharmaceuticals (ALXN) (americanbankingnews.com)
- Alexion Pharmaceuticals (ALXN) Price Target Cut to $170.00 by Analysts at Citigroup (americanbankingnews.com)
- Alexion Pharmaceuticals (ALXN) Given a $161.00 Price Target at Deutsche Bank (americanbankingnews.com)
- Morgan Stanley Increases Alexion Pharmaceuticals (ALXN) Price Target to $151.00 (americanbankingnews.com)
A number of equities research analysts have issued reports on the company. Evercore ISI upgraded Alexion Pharmaceuticals from an “in-line” rating to an “outperform” rating in a research report on Monday, February 5th. Leerink Swann decreased their price objective on Alexion Pharmaceuticals from $166.00 to $153.00 and set an “outperform” rating on the stock in a research report on Friday. Raymond James Financial restated an “outperform” rating and set a $130.00 price objective (down from $178.00) on shares of Alexion Pharmaceuticals in a research report on Thursday, January 4th. They noted that the move was a valuation call. Royal Bank of Canada upped their price objective on Alexion Pharmaceuticals to $166.00 in a research report on Tuesday, October 24th. Finally, TheStreet downgraded Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Friday, November 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and twenty-one have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $152.77.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.09 by $0.39. The firm had revenue of $909.70 million for the quarter, compared to analysts’ expectations of $880.38 million. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The company’s quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.26 earnings per share. sell-side analysts expect that Alexion Pharmaceuticals will post 6.25 EPS for the current year.
In related news, SVP Heidi L. Wagner sold 655 shares of the stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $117.26, for a total value of $76,805.30. Following the transaction, the senior vice president now owns 32,635 shares of the company’s stock, valued at $3,826,780.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Ludwig Hantson sold 2,553 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $121.63, for a total value of $310,521.39. Following the completion of the transaction, the chief executive officer now directly owns 36,172 shares in the company, valued at approximately $4,399,600.36. The disclosure for this sale can be found here. In the last three months, insiders sold 28,930 shares of company stock worth $3,378,199. 4.35% of the stock is owned by insiders.
ILLEGAL ACTIVITY NOTICE: “Alexion Pharmaceuticals (ALXN) Receiving Somewhat Positive News Coverage, Analysis Finds” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/alexion-pharmaceuticals-alxn-receiving-somewhat-positive-news-coverage-analysis-finds/1861997.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.